AI assistant
Spineway — Regulatory Filings 2018
Jan 4, 2018
1683_rns_2018-01-04_5b889d27-6e16-4bf1-a67d-fbaab04fbab2.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
LIQUIDITY CONTRACT ANNUAL REPORT
Regarding liquidity contract granted by SPINEWAY to PORTZAMPARC, the liquidity account held the following assets on 31st December 2017:
- § 21 622 shares SPINEWAY,
- § 28,569.76 €.
At June 30th 2017 report, the position of this liquidity contract was:
- § 20 570 shares SPINEWAY,
- § 33,865.96 €.
SPINEWAY IS ELIGIBLE FOR THE PEA-PME (EQUITY SAVINGS PLAN FOR SMES) Find out all about Spineway at www.spineway.com
Next communication: 2017 full year sales – January 17th 2018, after market closes.
Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column. Spineway has an international network of over 50 independent distributors and 90% of its turnover comes from exports. Spineway, which is eligible for investment through FCPIs (French unit trusts specializing in innovation), received the OSEO Excellence award as well as the Deloitte Fast 50 award in 2011. Rhône Alpes INPI Patent Innovation Award (2013) – Talent INPI award (2015). ISIN code: FR0011398874 - ALSPW
Investor Relations David Siegrist – Finance Director Tel: +33 (0)4 72 77 01 52 [email protected]
Financial Communication Jérôme Gacoin / Solène Kennis Tel: +33 (0)1 75 77 54 68 [email protected]